Neurocrine Biosciences has initiated a Phase 2 clinical trial evaluating NBI-1065890, an investigational VMAT2 inhibitor, in adults with tardive dyskinesia, following earlier Phase 1 safety and pharmacokinetic assessment.
Written By: Pharmacally Medical News Desk
Neurocrine Biosciences has initiated a Phase 2 clinical study evaluating NBI-1065890, an investigational next-generation VMAT2 inhibitor, in adults living with tardive dyskinesia (TD). The company announced that the trial is now underway as part of its continued effort to advance new treatment options for patients experiencing this chronic movement disorder.
The Phase 2 study is designed as a randomized, double-blind, placebo-controlled trial and is expected to enroll approximately 100 adult participants diagnosed with tardive dyskinesia. Neurocrine stated that the primary goal is to assess the compound’s efficacy, safety, and tolerability compared with placebo.
According to the company, the primary endpoint will measure the change from baseline in the Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score at Week 8, a widely used clinical tool for evaluating involuntary movements in TD.
NBI-1065890 is being developed as a potential differentiated therapy within the VMAT2 inhibitor class. Neurocrine noted that the candidate was designed with the possibility of a longer-acting profile, which could support improved dosing convenience and outcomes for patients over time.
Tardive dyskinesia is a serious neurological condition most often associated with long-term use of antipsychotic medications. It is characterized by repetitive, involuntary movements that can significantly affect daily functioning and quality of life.
Neurocrine has longstanding expertise in this field, having developed valbenazine (Ingrezza), the first FDA-approved treatment for tardive dyskinesia in 2017. The company continues to build on its experience in VMAT2 biology through pipeline advancements such as NBI-1065890.
The Phase 2 launch marks an important step in Neurocrine’s strategy to expand future therapeutic options for movement disorders, with additional updates expected as clinical development progresses.
Reference
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia, 26 January 2026, Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia | Neurocrine Biosciences